New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study-Reference-Cited by-同舟云学术

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Published:2017-02-18 Issue:5 Volume:92 Page:420-428
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Taher Ali T.¹^ORCID,Origa Raffaella²,Perrotta Silverio³,Kourakli Alexandra⁴,Ruffo Giovan Battista⁵,Kattamis Antonis⁶,Goh Ai‐Sim⁷,Cortoos Annelore⁸,Huang Vicky⁸,Weill Marine⁹,Merino Herranz Raquel⁹,Porter John B.¹⁰

Affiliation:

1. American University of Beirut Medical CenterBeirut Lebanon

2. Ospedale Pediatrico Microcitemico “A. Cao,”University of CagliariCagliari Italy

3. Department of PediatricsSecond University of NaplesNaples Italy

4. Hematology Division, Department of Internal MedicineUniversity of Patras Medical SchoolPatras Greece

5. U.O.C. Ematolog. Con Talassemia, A.O. Civico‐Di Cristina‐BenfratelliPalermo Italy

6. First Department of PediatricsUniversity of AthensAthens Greece

7. Department of MedicineHospital Pulau PinangGeorgetown Penang Malaysia

8. Novartis Pharmaceuticals CorporationEast Hanover New Jersey USA

9. Novartis Pharma AGBasel Switzerland

10. Department of HaematologyUniversity College LondonLondon UK

Funder